Compound file

Semaglutide

Semaglutide is an FDA-approved GLP-1 receptor agonist with extensive clinical evidence from 17,000+ trial participants. It demonstrates significant weight loss (15-20% body weight reduction) and cardiovascular benefits, with established safety data across multiple Phase III trials including SELECT (5-year, 17,604 participants) and OASIS 4 (307 participants for oral formulation).